Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 26 of 1,261
  1. US 12371420

    Polymorphs of Selinexor

    Karyopharm Therapeutics Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  2. US 12370195

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Aclaris Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  3. US 12370181

    Regimens of estrogen receptor antagonists

    Olema Pharmaceuticals, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  4. US 12369604

    Methods of inhibition with microbial strains and antibiotics

    MICROBIAL DISCOVERY GROUP, LLC · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  5. US 12370192

    Azole-fused pyridazin-3(2H)-one derivatives

    Takeda Pharmaceutical Company Limited · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  6. US 12370264

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  7. US 12371442

    Isoindolinone and indazole compounds for the degradation of EGFR

    C4 THERAPEUTICS, INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  8. US 12370241

    Nasal powder formulation for treatment of hypoglycemia

    Amphastar Pharmaceuticals, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  9. US 12371747

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  10. US 12371506

    Subcutaneous administration of anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  11. US 12371500

    Il-7R-alpha specific antibodies for treating acute lymphoblastic leukemia

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  12. US 12370163

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  13. US 2025235515

    CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS AND IMPROVED DRYING PROCESSES

    ABBVIE INC [US] · Granted Jul 24, 2025 · Expires Jul 19, 2045

    granted
  14. WO 2025153663

    LANDIOLOL COMPLEXÉ ENCAPSULÉ OU DISSOUS DANS UNE MATRICE LIPOPHILE

    AOP ORPHAN PHARMACEUTICALS GMBH [AT] · Granted Jul 24, 2025 · Expires Jul 19, 2045

    granted
  15. US 12365887

    CRISPR-Cas effector polypeptides and methods of use thereof

    The Regents of the University of California · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  16. US 12365889

    Tunable nanoscale cages from self-assembling DNA and protein building blocks

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  17. US 12365897

    RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  18. US 12365875

    Methods for generating skeletal muscle progenitor cells

    The Regents of the University of California · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  19. US 12365899

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  20. US 12364737

    Activin receptor type IIA variants and methods of use thereof

    Keros Therapeutics, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  21. US 12364683

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  22. US 12364688

    NSD family inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  23. US 12364791

    Conformal coating of biological surfaces

    Takeda Pharmaceutical Company Limited · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  24. US 12364670

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.